

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

CLINICAL BENEFIT	<input checked="" type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	9/1/2024

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Corneal Pachymetry

Corneal Pachymetry may be considered **medically necessary** when used as part of the medical management for any one of the following:

- Assessing progression of disease in individuals with endothelial dystrophies;
- Aiding in early diagnoses and treatment of graft failure and the need for re-grafting in corneal transplant recipients;
- To determine the response to the treatment of corneal transplant rejection;
- Assisting in the diagnosis of corneal thinning disorders; and
- To determine the influence of corneal thickness on intraocular pressure measurements for a glaucoma diagnosis, to include both glaucoma suspect and established glaucoma individuals.

Note: For the above indications, corneal pachymetry may be considered medically necessary only once per lifetime per eye except for those individuals undergoing corneal surgery, corneal transplant, and those being followed for ongoing corneal endothelial dystrophies and status-post corneal transplant.

Corneal Pachymetry is considered **not medically necessary** for the following:

- Performed as part of an evaluation for refractive surgery;
- Assessing the risk of corneal decompensation pre- and post-cataract surgery;
- Assisting in selection of appropriate cataract surgical techniques for individuals with prior intraocular surgery or established corneal diseases;
- Performed solely as a screening (e.g., no evidence to support diagnosis of glaucoma);
- Pre-operative evaluation (unless a corneal transplant is scheduled);

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

- Performed postoperatively (unless test is performed following corneal transplant)

Corneal endothelial microscopy (also known as endothelial cell photography, endothelial microscopy, or anterior segment photography)

Corneal endothelial microscopy may be considered **medically necessary** for any one of the following indications:

- As a pre-operative test before intraocular surgery (e.g., cataract surgery) to identify individuals at risk for postsurgical corneal decompensation.
- In the diagnosis and management of individuals with corneal dystrophies or other corneal abnormalities
- Are about to undergo a secondary intraocular lens implantation,
- Have had previous intraocular surgery and require cataract surgery,
- Are about to be fitted with extended wear contact lenses after intraocular surgery.

Transciliary Fistulization

Transciliary fistulization for the treatment of glaucoma is considered **investigational**, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with these procedures:

Corneal Collagen Cross-Linking

Corneal collagen cross-linking using riboflavin and ultraviolet A may be considered **medically necessary** as a treatment of progressive keratoconus (see policy guidelines for definition) or corneal ectasia after refractive surgery in patients who have failed conservative treatment (e.g. spectacle correction, rigid contact lens).

Corneal collagen cross-linking using riboflavin and ultraviolet A is considered **investigational** for all other indications as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

POLICY GUIDELINES

Progressive keratoconus or corneal ectasia is defined as 1 or more of the following:

- An increase of 1 D in the steepest keratometry value
- An increase of 1 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction
- A decrease ≥ 0.1 mm in the back optical zone radius in rigid contact lens wearers where other information was not available.

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

Cross-references:

MP 1.044 Corneal Surgery, Implantation of Intrastromal Corneal Ring Segment and Corneal Topography/Photokeratoscopy

MP 4.007 Vision Therapy

MP 4.042 Amniotic Membrane and Amniotic Fluid Injections

MP 9.011 Corneal Transplant, Endothelial Keratoplasty, and Keratoprotheses

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[TOP](#)

Corneal pachymetry

Corneal pachymetry using ultrasound is a specialized, noninvasive, ophthalmologic procedure that uses a pachymeter to measure corneal thickness. Measurements of central corneal thickness are performed by applying a topical anesthetic to the eye and placing an ultrasound probe on the central cornea where ultrasonic wave energy is passed into the eye.

Corneal pachymetry using ultrasound is primarily used to assist with the diagnosis, assessment, and/or monitoring of corneal diseases and to assess suspected or established glaucoma. For example, corneal pachymetry using ultrasound is used to assist with the diagnosis of corneal thinning disorders (e.g., keratoconus, keratoglobus, keratotorus, posterior keratoconus, pellucid marginal degeneration). Corneal pachymetry using ultrasound is also included in the assessment and/or monitoring of disease progression of many conditions or injury affecting the cornea such as Fuchs' endothelial dystrophy, posterior polymorphous dystrophy, corneal edema, endothelial disease from any etiology, bullous keratopathy, corneal ectasia, and corneal trauma.

Corneal pachymetry using ultrasound is an important component of the assessment and management of intraocular pressure and glaucoma. Corneal thickness is important because it can mask an accurate reading of intraocular pressure in glaucoma. Actual intraocular pressure may be underestimated in individuals with thinner central corneal thickness or overestimated in individuals with thicker central corneal thickness. Because intraocular pressure is reportedly the most important and only variable risk factor for glaucoma progression, knowledge of the central corneal thickness is important in managing individuals with either suspected or established glaucoma. Repeat measurements of central corneal thickness for suspect or established

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

glaucoma is not indicated unless the individual has corneal disease or has had surgery affecting corneal thickness. Corneal pachymetry for suspected or established glaucoma only needs to be performed once to obtain baseline glaucoma risk information.

In addition to assisting with the diagnosis, assessment, and/or the monitoring of corneal diseases and assessing suspected or established glaucoma, corneal pachymetry using ultrasound is valuable in the selection of appropriate surgical techniques and assessment of the individual's risk and response to certain ophthalmologic surgical procedures (e.g., corneal transplant surgery, cataract surgery). Corneal pachymetry using ultrasound is effective in aiding the early diagnosis and/or treatment of corneal transplant rejection, as well as assessing the response to treatment of corneal graft rejection. The procedure may be used to assess corneal graft health. Corneal pachymetry using ultrasound is also considered for assessing the risk of corneal decompensation before and after cataract surgery for individuals with endothelial disease.

Corneal Endothelial Microscopy

The cornea is the transparent structure that forms the anterior one sixth of the outer coat of the eye and is responsible for more than two thirds of its refractive power. The cornea consists of several layers, including the epithelium, stroma, and single-celled endothelium. The endothelium is the most posterior layer, interfacing with the aqueous humor of the anterior chamber of the eye. Corneal clarity is dependent on a relatively dehydrated state. The endothelium plays a key role in maintaining dehydration by both preventing aqueous humor from entering the cornea and by pumping fluid from the corneal stroma into the anterior chamber. The corneal endothelial cells do not replicate. When destroyed by disease or surgery, the remaining cells enlarge and spread out to cover the posterior corneal surface, thus decreasing the cell density (cell count). Corneas with extremely low endothelial cell densities can no longer maintain a dehydrated state. The corneas may decompensate, swell, and become cloudy over time, with an associated loss of visual acuity.

The slit lamp (or biomicroscope) is commonly used to assess the status of the cornea and corneal endothelium. However, the specular microscope provides a magnified view of a small area of corneal endothelial cells to measure and record endothelial cell counts of the cornea. This technique is also known as corneal endothelial microscopy. Images of the endothelium seen with specular microscopy can be recorded on videotape or photographic film to facilitate estimates of endothelial cell density and configuration. The cell density of an individual's cornea can then be compared to a previously documented normal range, allowing for a rough estimation of the ability of that cornea to withstand damage from surgical or other trauma.

Corneal endothelial microscopy has been frequently used as a pre-operative test before intraocular surgery to identify patients at risk for corneal decompensation after surgery. In this setting, the most common application has been cataract surgery. In addition, corneal endothelial microscopy has been used in patients with corneal endothelial dystrophies, including Fuchs' endothelial dystrophy, posterior polymorphous dystrophy, and iridocorneal endothelial syndromes. Finally, specular microscopy has been widely used in the evaluation of donor tissue for corneal transplantation.

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

Transciliary Fistulization for the Treatment of Glaucoma

Transciliary fistulization, also known as transciliary filtration or Singh filtration, uses a thermocauterization device called the Fugo blade to create a pore in the posterior chamber of the eye from the sclera through the ciliary body. This procedure reduces intraocular pressure (IOP) in patients with glaucoma by allowing aqueous fluid to seep into the subconjunctival lymphatic system.

Glaucoma is a disease characterized by degeneration of the optic disc. Elevated intraocular pressure (IOP) has long been thought to be the primary etiology, but the relationship between IOP and optic nerve damage varies among patients, suggesting a multifactorial origin. For example, some patients with clearly elevated IOP will show no damage to the optic nerve, while other patients with marginal or no pressure elevation will, nonetheless, show optic nerve damage. The association between glaucoma and other vascular disorders, such as diabetes or hypertension, suggests vascular factors may play a role in glaucoma. Specifically, it has been hypothesized that reductions in blood flow to the optic nerve may contribute to the visual field defects associated with glaucoma.

For primary-open angle glaucoma (POAG) associated with IOP, a decrease in aqueous outflow through the trabecular meshwork is believed to cause the IOP. However, there are many theories on what causes the decrease in aqueous outflow such as foreign body obstruction, trabecular endothelial cell loss, reduced trabecular pore density, disturbances in neurofeedback mechanisms, or normal phagocytic activity.

IOPs above 21 mm Hg have been shown to increase rates of visual field loss, and conventional management of the patient principally involves drug therapy to control elevated IOP to prevent or delay glaucomatous loss of vision. For POAG, drug therapy may include alpha-agonist, beta-blockers, carbonic-anhydrase inhibitors, miotic agents, and prostaglandin analogs. When the maximum tolerated medical therapy fails to control optic neuropathy, surgical care is considered the next treatment option. Surgical procedures include laser trabeculoplasty, incisional or filtering surgery, such as trabeculectomy or drainage implants, and as a last resort, ablation of the ciliary body.

Transciliary fistulization for the treatment of glaucoma, also known as transciliary filtration or Singh filtration, is a recent approach to filtering surgery. This procedure uses a thermocauterization device called the Fugo blade to create a plasma-ablated pore or filter track from the sclera through the ciliary body to allow aqueous fluid to ooze into the subconjunctival lymphatics from the posterior chamber (behind the iris) of the eye. Plasma ablation with the Fugo blade allows the highly vascular ciliary body to be penetrated with little or no bleeding.

Transciliary fistulization allows aqueous fluid to drain from the posterior chamber of the eye and differs from conventional filtering surgeries, such as trabeculoplasty, trabeculectomy, and drainage implant surgery, in which aqueous fluid is filtered from the anterior chamber of the eye. In the trabeculoplasty procedure, a laser is used to burn small areas of the trabecular meshwork,

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

where normal drainage of the eye occurs, to increase aqueous fluid outflow, thereby lowering IOP. In trabeculectomy (or glaucoma filtration procedure), a portion of trabecular meshwork is surgically removed through a superficial flap of sclera to lower IOP by creating an alternate pathway for the aqueous fluid to flow from the anterior chamber to a bleb created in the subconjunctival space. If trabeculectomy has failed to reduce IOP sufficiently or a patient is considered to be at high risk for trabeculectomy failure, drainage implant surgery may be considered in which a tube is placed in the anterior chamber to shunt aqueous fluid to the subconjunctival space and lower IOP. Both trabeculectomy and drainage implant surgery often result in flat or collapsed anterior chambers and usually require that an iridectomy (placement of a hole in the iris) also be performed. Transciliary fistulization rarely requires an iridectomy and is thought to reduce tissue damage and risk of scarring and other complications associated with trabeculectomy and drainage implant surgery.

Corneal Collagen Cross-Linking

Keratoconus and Ectasia

Keratoconus is a bilateral dystrophy characterized by progressive ectasia (paracentral steepening and stromal thinning) that impairs visual acuity. While frequently diagnosed at a young age, the progression of keratoconus is variable. Results from a longitudinal study with 7 years of follow-up showed that, over the study period, there was a decrease of 2 high- and 4 low-contrast letters in best-corrected visual acuity (BCVA). About 1 in 5 patients showed a decrease of 10 or more letters in high-contrast visual acuity and one-third of patients showed a decrease of 10 or more letters in low-contrast visual acuity. Over 8 years of follow-up, there was a mean increase of 1.44 diopters (D) in First Definite Apical Clearance Lens (a rigid contact lens to measure corneal curvature) and 1.6 D in flatter keratometric reading.

Ectasia (also known as keratectasia, iatrogenic keratoconus, or secondary keratoconus) is a serious long term complication of laser in situ keratomileusis (LASIK) surgery and photorefractive keratectomy. It is similar to keratoconus, but occurs postoperatively and primarily affects older populations. It may result from unrecognized preoperative keratoconus or, less frequently, from the surgery itself. Similar to keratoconus, it is characterized by progressive thinning and steepening of the cornea, resulting in corneal optical irregularities and loss of visual acuity.

Treatment

The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis, although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line of

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs and intracorneal ring segments. Frequently, penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of the disease, and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking has the potential to slow the progression of the disease. It is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet A irradiation. There are 2 protocols for corneal collagen cross-linking:

1. Epithelium-off corneal collagen cross-linking (also known as “epi-off”): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and ultraviolet A causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-µm thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.
2. Epithelium-on corneal collagen cross-linking (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed.

Currently, the only corneal collagen cross-linking treatment approved by the U.S. Food and Drug Administration (FDA) is the epithelium-off method. There are no FDA approved corneal collagen cross-linking treatments using the epithelium-on method. Corneal collagen cross-linking is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking may also have anti-edematous and antimicrobial properties.

Regulatory Status

In 2016, riboflavin 5'-phosphate in 20% dextran ophthalmic solution (Photrexa Viscous®; Avedro) and riboflavin 5'-phosphate ophthalmic solution (Photrexa®; Avedro) were approved by the U.S. Food and Drug Administration for use with KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery.

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

IV. RATIONALE

[TOP](#)

Transciliary Filtration

The limited literature suggests poor acceptance of this procedure by the ophthalmologic community; the reasons for this are not clear. While this procedure is similar to other filtration procedures commonly performed for the surgical treatment of glaucoma, further studies with longer term follow-up are needed. Overall, the data are insufficient to determine the long-term health outcomes of transciliary fistulization for the treatment of glaucoma.

Corneal Collagen Cross-Linking

Summary of Evidence

For individuals who have progressive keratoconus who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes multiple randomized controlled trials (RCTs), systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary endpoint (an intermediate outcome) of reducing maximum corneal curvature by 1 diopter (D) was achieved at month 3 and maintained at months 6 and 12 in corneal collagen cross-linking treated patients compared with sham controls. In both RCTs, the difference in mean change in maximum corneal curvature from baseline to 12 months was 1.9 D and 2.3 D, respectively, favoring the corneal collagen cross-linking treated patients. Several other studies measured visual acuity and found significant and lasting improvements in corrected visual acuity and other measures with corneal collagen cross-linking. Long-term follow-up for visual acuity outcomes is needed. The adverse events associated with corneal collagen cross-linking include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but continued in a few (1%-6%) patients for 6 to 12 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have corneal ectasia after refractive surgery who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes multiple RCTs and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary endpoint (an intermediate outcome) of reducing maximum corneal curvature by 1 D was achieved at month 3 and maintained at months 6 and 12 in the corneal collagen cross-linking treated patients compared with sham controls. In both RCTs, the difference in mean change in maximum corneal curvature from baseline to 12 months was 2.0 D and 1.1 D, respectively, favoring corneal collagen cross-linking treated patients. Other trials showed significant improvements not only in maximum corneal curvature but also visual acuity measures in the corneal collagen cross-linking groups compared with the control groups. The first and longest trial followed patients up to 3 years and saw continued improvement in visual acuity with corneal collagen cross-linking. Long-term follow-up for visual acuity outcomes is needed. The adverse events associated with corneal collagen cross-linking were the same for the ectasia trials as for the keratoconus. The

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

APHAKIA refers to the absence of the lens of an eye, occurring congenitally or as a result of trauma or surgery.

AMBLYOPIA refers to reduced vision in an eye not correctable by a manifest refraction and with no obvious pathologic or structural cause.

CORNEA refers to the transparent anterior portion of the sclera (the fibrous outer layer of the eyeball), about one sixth of its surface: the first part of the eye that refracts light.

CORNEAL PACHYMETRY is a measurement of the thickness of the cornea. A pachymeter is most often used to measure the central cornea.

ENDOTHELIUM refers to the layer of simple squamous epithelial cells that line the heart, the blood and the lymph vessels, and the serous cavities of the body.

EYE EXAMINATION is a medical examination (e.g., office visit) performed by a physician when the reported symptom/diagnosis is, or could be, related to the eye.

INTRAOCULAR LENS is a mechanical transplant used in ophthalmology to replace the natural lens of the eye that has ceased to function due to disease (e.g., cataract) or otherwise functionally disrupted.

ORTHOPTICS is the science of correcting defects in binocular vision resulting from defects in optic musculature.

PSEUDOPHAKIA is a condition in which the natural lens of the eye is replaced with an intraocular lens.

REFRACTION is a routine test used by eye specialists to measure refractive errors of the eye.

REFRACTIVE ERRORS are eye conditions correctable with eyeglasses (e.g., myopia, astigmatism).

ROUTINE EYE CARE consists of eye examinations or refractions reported without a symptomatic condition, disease, injury, or defect related to the eye.

ROUTINE VISION SCREENINGS are periodic examinations to detect eye or vision problems and conditions such as macular degeneration, cataracts, and glaucoma, which can cause blindness if left untreated.

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits, do not constitute medical advice, and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered when used for transciliary fistulization for the treatment of glaucoma:

Procedure Codes							
66999							

Covered when medically necessary; corneal pachymetry for the following indications. All other indications are considered not medically necessary:

***Considered medically necessary only once per lifetime per eye except for those patients undergoing corneal surgery, corneal transplant, and those being followed for ongoing corneal endothelial dystrophies and status-post corneal transplant.*

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

Procedure Codes							
76514							

ICD-10-CM Diagnosis Codes							
H18.51	H18.52	H18.53	H18.54	H18.55	H18.59	H18.891	H18.892
H18.893	H40.011	H40.012	H40.013	H40.021	H40.022	H40.023	H40.031
H40.032	H40.033	H40.041	H40.042	H40.043	H40.051	H40.052	H40.053
H40.061	H40.062	H40.063	H40.1111	H40.1112	H40.1113	H40.1114	H40.1121
H40.1122	H40.1123	H40.1124	H40.1131	H40.1132	H40.1133	H40.1134	H40.1211
H40.1212	H40.1213	H40.1214	H40.1221	H40.1222	H40.1223	H40.1224	H40.1231
H40.1232	H40.1233	H40.1234	H40.1311	H40.1312	H40.1313	H40.1314	H40.1321
H40.1322	H40.1323	H40.1324	H40.1331	H40.1332	H40.1333	H40.1334	H40.1411
H40.1412	H40.1413	H40.1414	H40.1421	H40.1422	H40.1423	H40.1424	H40.1431
H40.1432	H40.1433	H40.1434	H40.151	H40.152	H40.153	H40.211	H40.212
H40.2211	H40.2212	H40.2213	H40.2214	H40.2221	H40.2222	H40.2223	H40.2224
H40.2231	H40.2232	H40.2233	H40.2234	H40.231	H40.232	H40.233	H40.241
H40.242	H40.243	H40.31X1	H40.31X2	H40.31X3	H40.31X4	H40.32X1	H40.32X2
H40.32X3	H40.32X4	H40.33X1	H40.33X2	H40.33X3	H40.33X4	H40.41X1	H40.41X2
H40.41X3	H40.41X4	H40.42X1	H40.42X2	H40.42X3	H40.42X4	H40.43X1	H40.43X2
H40.43X3	H40.43X4	H40.51X1	H40.51X2	H40.51X3	H40.51X4	H40.52X1	H40.52X2
H40.52X3	H40.52X4	H40.53X1	H40.53X2	H40.53X3	H40.53X4	H40.61X1	H40.61X2
H40.61X3	H40.61X4	H40.62X1	H40.62X2	H40.62X3	H40.62X4	H40.63X1	H40.63X2
H40.63X3	H40.63X4	H40.811	H40.812	H40.813	H40.821	H40.822	H40.823
H40.831	H40.832	H40.833	H40.89	H42	H44.511	H44.512	H44.513
T86.840	T86.841	Z94.7					

Covered when medically necessary, corneal endothelial microscopy (also known as endothelial cell photography, endothelial microscopy, or anterior segment photography):

Procedure Codes							
92286							

ICD-10-CM Diagnosis Codes							
H17.11	H17.12	H17.13	H18.011	H18.012	H18.013	H18.051	H18.052
H18.053	H18.061	H18.062	H18.063	H18.51	H18.52	H18.53	H18.54
H18.55	H18.59	H18.711	H18.712	H18.713	H18.719	H18.891	H18.892

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

H18.893	L12.0	L12.1	L12.2	L12.31	L12.35	L12.8	Z01.818
Z46.0	Z94.7	Z96.1					

Covered when medically necessary, corneal collagen cross linking:

Procedure Codes							
0402T	J2787						

ICD-10-CM Diagnosis Codes							
H18.601	H18.602	H18.603	H18.609	H18.611	H18.612	H18.613	H18.619
H18.621	H18.622	H18.623	H18.629				

IX. REFERENCES

[TOP](#)

Taber’s Cyclopedic Medical Dictionary, 19th edition.

1. *The Free Medical Dictionary.*

Transciliary Fistulization for the Treatment of Glaucoma

1. Singh D, Singh K. Transciliary filtration using the Fugo Blade. *Ann Ophthalmol* 2002; 34(3):183-7.
2. Dow CT, deVenecia G. Transciliary filtration (Singh filtration) with the Fugo plasma blade. *Ann Ophthalmol* 2008; 40(1):8-14.
3. Fan Gaskin JC, Nguyen DQ, Soon Ang G, O'Connor J, Crowston JG. Wound Healing Modulation in Glaucoma Filtration Surgery-Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I). *J Curr Glaucoma Pract.* 2014;8(2):37-45. PMID 26997807 PMID PMC4741165
4. Blue Cross Blue Shield Association Medical Policy Reference Manual. 9.03.17 Transciliary Fistulization for the Treatment of Glaucoma. February 2012 (Archived).

Corneal Pachymetry

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002; 120(6):701-830. doi:10.1001/archoph.120.6.701
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002; 120(6):714-830. doi:10.1001/archoph.120.6.714
3. American Academy of Ophthalmology. *Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma Suspect.* San Francisco, CA: American Academy of Ophthalmology; 2015.
4. American Academy of Ophthalmology. *Refractive Management/Intervention Panel. Preferred Practice Pattern® Guidelines. Refractive errors and refractive surgery.* San Francisco, CA: American Academy of Ophthalmology; 2017

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

5. Hammer A, Heeren TFC, Angunawela R, Marshall J, Saha K. A Novel Role for Corneal Pachymetry in Planning Cataract Surgery by Determining Changes in Spherical Equivalent Resulting from a Previous LASIK Treatment. *J Ophthalmol.* 2023;2023:2261831. Published 2023 May 31. PMID 37483313 PMCID PMC10362985

Corneal Endothelial Microscopy

1. Cataract Management Guideline Panel. *Cataract in Adults: Management of Functional Impairment.* Rockville, MD. AHCPR Publication no. 93-0542, 1993
2. American Academy of Ophthalmology. *Corneal endothelial photography.* *Ophthalmology* 1991; 98(9):1464–8
3. Elshalkami MA, Abdalla TMM, Abdellatif MK, Fawzy SM. Assessment of corneal endothelial cell parameters using specular microscopy in previously infected SARS-CoV-2 patients. *Int Ophthalmol.* 2023;43(8):2983-2987. PMID 36906646 PMCID PMC10008069
4. Blue Cross Blue Shield Association Medical Policy Reference Manual. 9.03.04 Corneal Endothelial Microscopy/Specular Microscopy. June 2009 (Archived)

Collagen Cross-Linking

1. Avedro Inc. *Photorexa Viscous and Photorexa Prescribing Label.* 2016; [label \(fda.gov\)](http://label(fda.gov)) July 14, 2021
2. Davis LJ, Schechtman KB, Wilson BS, et al. Longitudinal changes in visual acuity in keratoconus. *Invest Ophthalmol Vis Sci.* Feb 2006; 47(2): 489-500. PMID 16431941
3. McMahan TT, Edrington TB, Szczołka-Flynn L, et al. Longitudinal changes in corneal curvature in keratoconus. *Cornea.* Apr 2006; 25(3): 296-305. PMID 16633030
4. Center for Drug Evaluation and Research. *Application Number 203324Orig2s000. Summary Review*
5. Hersh PS, Greenstein SA, Fry KL. Corneal collagen crosslinking for keratoconus and corneal ectasia: One-year results. *J Cataract Refract Surg.* Jan 2011; 37(1): 149-60. PMID 21183110
6. Hersh PS, Stulting RD, Muller D, et al. *United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment.* *Ophthalmology.* Sep 2017; 124(9): 1259-1270. PMID 28495149
7. Renesto Ada C, Barros Jde N, Campos M. Impression cytologic analysis after corneal collagen cross-linking using riboflavin and ultraviolet-A light in the treatment of keratoconus. *Cornea.* Oct 2010; 29(10): 1139-44. PMID 20622670
8. Sykakis E, Karim R, Evans JR, et al. Corneal collagen cross-linking for treating keratoconus. *Cochrane Database Syst Rev.* Mar 24, 2015; (3): CD010621. PMID 25803325
9. Meiri Z, Keren S, Rosenblatt A, et al. Efficacy of Corneal Collagen Cross-Linking for the Treatment of Keratoconus: A Systematic Review and Meta-Analysis. *Cornea.* Mar 2016; 35(3): 417-28. PMID 26751990
10. McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and meta-analysis. *Acta Ophthalmol.* May 2017; 95(3): 229-239. PMID 27678078

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

11. Toprak I, Yaylali V, Yildirim C. Visual, Topographic, and Pachymetric Effects of Pediatric Corneal Collagen Cross-linking. *J Pediatr Ophthalmol Strabismus*. Mar 01 2017; 54(2): 84-89. PMID 27668869
12. Badawi AE. Accelerated corneal collagen cross-linking in pediatric keratoconus: One year study. *Saudi J Ophthalmol*. Jan-Mar 2017; 31(1): 11-18. PMID 28337057
13. Knutsson KA, Paganoni G, Matuska S, et al. Corneal collagen cross-linking in paediatric patients affected by keratoconus. *Br J Ophthalmol*. Feb 2018; 102(2): 248-252. PMID 28655729
14. Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. *Cornea*. Jan 2016; 35(1): 62-71. PMID 26509768
15. Padmanabhan P, Rachapalle Reddi S, Rajagopal R, et al. Corneal Collagen Cross-Linking for Keratoconus in Pediatric Patients-Long-Term Results. *Cornea*. Feb 2017; 36(2): 138-143. PMID 28060058
16. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. *J Cataract Refract Surg*. May 2008; 34(5): 796-801. PMID 18471635
17. Raiskup F, Theuring A, Pillunat LE, et al. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. *J Cataract Refract Surg*. Jan 2015; 41(1): 41-6. PMID 25532633
18. Caporossi A, Mazzotta C, Baiocchi S, et al. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. *Am J Ophthalmol*. Apr 2010; 149(4): 585-93. PMID 20138607
19. Hersh PS, Stulting RD, Muller D, et al. U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery. *Ophthalmology*. Oct 2017; 124(10): 1475-1484. PMID 28655538
20. Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. *J Refract Surg*. Sep 2008; 24(7): S720-5. PMID 18811118
21. Wittig-Silva C, Chan E, Islam FM, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology*. Apr 2014; 121(4): 812-21. PMID 24393351
22. National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013.
23. Kandel, H., Abbondanza, M., Gupta, A. et al. Comparison of standard versus accelerated corneal collagen cross-linking for keratoconus: 5-year outcomes from the Save Sight Keratoconus Registry. *Eye* 38, 95–102 (2024)
24. Blue Cross Blue Shield Association Medical Policy Reference Manual. 9.03.28 Corneal Collagen Cross-Linking. April 2024

X. POLICY HISTORY

[TOP](#)

MP 2.028	06/15/2020: Consensus Review: No change to Policy Statement. Product
-----------------	---

MEDICAL POLICY

POLICY TITLE	EYE CARE
POLICY NUMBER	MP 2.028

	Variation updated. Coding reviewed, no changes. References reviewed and updated.
	07/14/2021: Consensus Review. Updated FEP, Background, Rationale, and References. No changes to coding. Updated coding tables for ICD-10 and HCPCS.
	06/06/2022 Consensus Review. No change to policy statement. Product Variations updated. Coding table format updated. References reviewed and updated.
	04/14/2023 Consensus Review. No change to policy statement. References reviewed and updated. Coding reviewed.
	05/09/2024 Consensus Review. No change to policy statement. References reviewed and updated. Coding reviewed with no changes.

[TOP](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.